Table 2 from Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
收藏数据链接：
官方服务：
资源简介：
Most frequently reported AEs in >15% of patients with CS receiving ivosidenib.
创建时间：
2025-06-03
